Quarterly report · Q2

Period2023-01-01 → 2023-06-30
Filed2023-08-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥501m2023-01-01 → 2023-06-30Cons.Net sales
Revenue¥1.4bn2022-01-01 → 2022-12-31Cons.Net sales (5-year summary)
Revenue¥840m2022-01-01 → 2022-06-30Cons.Net sales
Operating income−¥864m2023-01-01 → 2023-06-30Cons.Operating income
Operating income−¥312m2022-01-01 → 2022-06-30Cons.Operating income
Ordinary income−¥868m2023-01-01 → 2023-06-30Cons.Ordinary income
Ordinary income−¥1.3bn2022-01-01 → 2022-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥306m2022-01-01 → 2022-06-30Cons.Ordinary income
Profit before tax−¥869m2023-01-01 → 2023-06-30Cons.Income before income taxes
Profit before tax−¥349m2022-01-01 → 2022-06-30Cons.Income before income taxes
Net income (owners)−¥886m2023-01-01 → 2023-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥1.3bn2022-01-01 → 2022-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥359m2022-01-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income−¥886m2023-01-01 → 2023-06-30Cons.Profit loss
Net income−¥359m2022-01-01 → 2022-06-30Cons.Profit loss
Total assets¥4.6bnat 2023-06-30Cons.Assets
Total assets¥4.3bnat 2022-12-31Cons.Assets
Total assets¥5.2bnat 2022-06-30Cons.Total assets (5-year summary)
Total liabilities¥453mat 2023-06-30Cons.Liabilities
Total liabilities¥625mat 2022-12-31Cons.Liabilities
Net assets / equity¥4.1bnat 2023-06-30Cons.Net assets
Net assets / equity¥3.6bnat 2022-12-31Cons.Net assets
Net assets / equity¥4.4bnat 2022-06-30Cons.Net assets (5-year summary)
Cash and deposits¥3.7bnat 2023-06-30Cons.Cash and deposits
Cash and deposits¥3.4bnat 2022-12-31Cons.Cash and deposits
Cash & equivalents¥3.7bnat 2023-06-30Cons.Cash and cash equivalents
Cash & equivalents¥3.4bnat 2022-12-31Cons.Cash and cash equivalents
Cash & equivalents¥4.7bnat 2022-06-30Cons.Cash and cash equivalents
Cash & equivalents¥3.8bnat 2021-12-31dCons.Cash and cash equivalents
Operating cash flow−¥939m2023-01-01 → 2023-06-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥708m2022-01-01 → 2022-12-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥585m2022-01-01 → 2022-06-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥7m2023-01-01 → 2023-06-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥126m2022-01-01 → 2022-12-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥57m2022-01-01 → 2022-06-30Cons.Net cash provided by used in investment activities
Financing cash flow¥1.2bn2023-01-01 → 2023-06-30Cons.Net cash provided by used in financing activities
Financing cash flow¥367m2022-01-01 → 2022-12-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥166m2022-01-01 → 2022-06-30Cons.Net cash provided by used in financing activities
EPS (basic)¥-53.812023-01-01 → 2023-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-21.462023-04-01 → 2023-06-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-99.12022-01-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-26.532022-01-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-25.252022-04-01 → 2022-06-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio89.9%at 2023-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio85.0%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio84.7%at 2022-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 10
SegmentItemPeriodValue
jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segmentsegment profit2023-01-01 → 2023-06-30−¥1.0bn
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue2023-01-01 → 2023-06-30¥501m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue external2023-01-01 → 2023-06-30¥501m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentsegment profit2023-01-01 → 2023-06-30¥169m
jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥286m
jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥286m
jpcrp040300-q2r_E00987-000Drug Discovery Businessreportable segmentsegment profit2022-01-01 → 2022-06-30−¥547m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue2022-01-01 → 2022-06-30¥553m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentrevenue external2022-01-01 → 2022-06-30¥553m
jpcrp040300-q2r_E00987-000Drug Discovery Support Businessreportable segmentsegment profit2022-01-01 → 2022-06-30¥235m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 424
ItemContextValueUnit
Number of shares heldCurrentQuarterInstant_No1MajorShareholdersMember532677
Shareholding ratioCurrentQuarterInstant_No1MajorShareholdersMember0.0311
Number of shares heldCurrentQuarterInstant_No2MajorShareholdersMember504500
Shareholding ratioCurrentQuarterInstant_No2MajorShareholdersMember0.0294
Number of shares heldCurrentQuarterInstant_No3MajorShareholdersMember474600
Shareholding ratioCurrentQuarterInstant_No3MajorShareholdersMember0.0277
Number of shares heldCurrentQuarterInstant_No4MajorShareholdersMember372466
Shareholding ratioCurrentQuarterInstant_No4MajorShareholdersMember0.0217
Number of shares heldCurrentQuarterInstant_No5MajorShareholdersMember358000
Shareholding ratioCurrentQuarterInstant_No5MajorShareholdersMember0.0209
Number of shares heldCurrentQuarterInstant_No6MajorShareholdersMember333900
Shareholding ratioCurrentQuarterInstant_No6MajorShareholdersMember0.0195
Number of shares heldCurrentQuarterInstant_No7MajorShareholdersMember277700
Shareholding ratioCurrentQuarterInstant_No7MajorShareholdersMember0.0162
Number of shares heldCurrentQuarterInstant_No8MajorShareholdersMember270300
Shareholding ratioCurrentQuarterInstant_No8MajorShareholdersMember0.0158
Number of shares heldCurrentQuarterInstant_No9MajorShareholdersMember262035
Shareholding ratioCurrentQuarterInstant_No9MajorShareholdersMember0.0153
Number of shares heldCurrentQuarterInstant_No10MajorShareholdersMember261900
Shareholding ratioCurrentQuarterInstant_No10MajorShareholdersMember0.0153
Number of shares heldCurrentQuarterInstant3648078
Shareholding ratioCurrentQuarterInstant0.2133
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithNoVotingRightsMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of voting rights issued shares voting rightsCurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember-
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember7100
Number of voting rights issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember170876
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember17087600
Number of shares issued shares voting rightsCurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember7200
Number of shares issued shares voting rightsCurrentQuarterInstant17101900
Number of voting rights issued shares voting rightsCurrentQuarterInstant170876
Number of shares held in own name treasury shares etcCurrentQuarterInstant_Row1Member7100
Number of shares held in others names treasury shares etcCurrentQuarterInstant_Row1Member-
Total number of shares held treasury shares etcCurrentQuarterInstant_Row1Member7100
Shareholding ratio treasury shares etcCurrentQuarterInstant_Row1Member0.0004
Number of shares held in own name treasury shares etcCurrentQuarterInstant7100
Number of shares held in others names treasury shares etcCurrentQuarterInstant-
Total number of shares held treasury shares etcCurrentQuarterInstant7100
Shareholding ratio treasury shares etcCurrentQuarterInstant0.0004
Cash and depositsPrior1YearInstant3379048000JPY
Cash and depositsCurrentQuarterInstant3684625000JPY
Accounts receivable tradePrior1YearInstant182426000JPY
Accounts receivable tradeCurrentQuarterInstant194692000JPY
Merchandise and finished goodsPrior1YearInstant84450000JPY
Merchandise and finished goodsCurrentQuarterInstant87690000JPY
Work in processPrior1YearInstant5918000JPY
Work in processCurrentQuarterInstant11264000JPY
Raw materials and suppliesPrior1YearInstant28163000JPY
Raw materials and suppliesCurrentQuarterInstant40964000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-12-31pass
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net assetsconsolidated 2023-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-01-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2022-01-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2023-01-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-01-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-01-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2022-12-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass